BioCentury
ARTICLE | Company News

Eisai submits first products for South African approval

January 30, 2013 2:27 AM UTC

Eisai Co. Ltd. (Tokyo:4523; Osaka:4523) said it submitted regulatory applications to South Africa's Medicines Control Council (MCC) for Halaven eribulin for metastatic breast cancer and Fycompa permpa...